--- title: Is Plasmid DNA Limiting Your Program? | Artis BioSolutions description: "Kate Broderick on synthetic DNA: no bacterial fermentation, no antibiotic resistance gene, weeks instead of months. Watch the Cell and Gene conversation." --- [![Artis BioSolutions](https://go.artisbiosolutions.com/hubfs/logo_artis_landscape%202.svg)](https://artisbiosolutions.com) - [Home](https://artisbiosolutions.com) - [Contact](https://artisbiosolutions.com/contact) Free Video, 20 Minutes # The Case for Synthetic DNA in Modern Therapeutic Development What Changes When the Starting Material Is Made Rather Than Grown Removing bacterial fermentation removes the antibiotic resistance gene, the endotoxin profile and the nine month lead time in a single step. Kate Broderick, our Chief Scientific and Innovation Officer, works through what that changes with Cell and Gene. - WeeksNot Months, From Sequence to Starting Material - ZeroBacterial Fermentation in the Process - 20 MinThe Full Conversation [![1705601848264 (2)](https://go.artisbiosolutions.com/hs-fs/hubfs/1705601848264%20(2).jpg?width=795&height=795&name=1705601848264%20(2).jpg "1705601848264 (2)") Free Video Kate Broderick on Synthetic DNA](https://go.artisbiosolutions.com/cell-and-gene-the-case-for-synthetic-dna-in-modern-therapeutic-development#video-form) [Watch the Conversation](https://go.artisbiosolutions.com/cell-and-gene-the-case-for-synthetic-dna-in-modern-therapeutic-development#video-form) Free Download ## Watch the Conversation Twenty minutes with Kate Broderick, free and yours in one click. We’ll only use your information to send you the video and occasional updates on synthetic DNA and genetic medicines manufacturing. Unsubscribe anytime. What’s Included ## A Straight Answer on Whether Plasmid Is Still Good Enough The race to accelerate therapeutic development is forcing the industry to rethink one of its most fundamental starting materials. Kate Broderick has spent more than 25 years in nucleic acid medicine, DNA and RNA vaccine development, and delivery. In this conversation she covers what synthetic DNA removes from a process, where it fits across modalities, and what has to be true before a program switches. ### What It Removes No bacterial fermentation, which means no antibiotic resistance gene and no endotoxin profile to defend in a regulatory meeting. ### Weeks Instead of Months An enzymatic, sequence agnostic process, so turnaround does not depend on whether the bacteria cooperate with your sequence. ### Where It Fits First mRNA via in vitro transcription, DNA as an API, AAV and viral vector construction, CAR-T and CRISPR. What’s Inside ## What the Conversation Covers ![](https://go.artisbiosolutions.com/hubfs/Artis-Icons_oDNA.svg) ### Why the Starting Material Touches Everything DNA flows to RNA flows to protein, so the material at the start of the process reaches every downstream decision. ![](https://go.artisbiosolutions.com/hubfs/Icons-6%20(1).svg) ### What Leaves the Regulatory Conversation The antibiotic resistance gene and the endotoxin profile go with the fermentation, and that changes what can be argued to a regulator. ![](https://go.artisbiosolutions.com/hubfs/Icons-2-1%20(1).svg) ### Weeks Instead of Months What a lead time measured in days does to a development plan that was built around nine month cycles. ![](https://go.artisbiosolutions.com/hubfs/Artis-icons_Partnership.svg) ### Where It Fits Across Modalities RNA therapeutics, cell and gene therapy, outbreak response and personalised cancer treatment. ![](https://go.artisbiosolutions.com/hubfs/Artis-icons_Speed.svg) ### What Has to Be True Before You Switch The questions worth putting to any synthetic DNA supplier, including this one. Recorded with **Cell & Gene**. Presented by **Kate Broderick, Ph.D.**, Chief Scientific and Innovation Officer, Artis BioSolutions. Still Planning Around Plasmid? We can run your sequence as synthetic DNA and show you the comparison against your current material, on your own process. [Start a Conversation](https://artisbiosolutions.com/contact) #### [Services](https://artisbiosolutions.com/services) - [Process Development](https://artisbiosolutions.com/services/process-development) - [Analytical Development](https://artisbiosolutions.com/services/analytical-development) - [GMP Manufacturing](https://artisbiosolutions.com/services/gmp-manufacturing) - [CMC Strategy](https://artisbiosolutions.com/services/cmc-strategy) [![LinkedIn](https://go.artisbiosolutions.com/hubfs/LinkedIn.svg)](https://www.linkedin.com/company/artisbiosolutions/) #### [Synthetic DNA](https://artisbiosolutions.com/synthetic-dna) - [Why Cell-Free DNA](https://artisbiosolutions.com/synthetic-dna/why-cell-free-dna) - [oDNA Platform](https://artisbiosolutions.com/synthetic-dna/odna-platform) #### [Therapeutic Modalities](https://artisbiosolutions.com/therapeutic-modalities) - [Cell Therapy](https://artisbiosolutions.com/therapeutic-modalities/cell-therapy) - [Viral Vectors](https://artisbiosolutions.com/therapeutic-modalities/viral-vectors) - [Non-Viral Delivery](https://artisbiosolutions.com/therapeutic-modalities/non-viral-delivery) #### [Company](https://artisbiosolutions.com/company/about) - [About](https://artisbiosolutions.com/company/about) - [Facilities](https://artisbiosolutions.com/company/facilities) - [Partnering](https://artisbiosolutions.com/company/partnering) - [Resources](https://artisbiosolutions.com/company/resources) - [Contact](https://artisbiosolutions.com/contact) [![Artis BioSolutions](https://go.artisbiosolutions.com/hubfs/logo_artis_landscape%202.svg)](https://artisbiosolutions.com)